CWP
AVIR icon

Curated Wealth Partners’s Atea Pharmaceuticals AVIR Stock Holding History

Curated Wealth Partners’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$671K Buy
+695,000
New +$3.46M 0.09% 208

Other funds holding AVIR

CAC
Certified Advisory Corp Altamonte Springs, Florida $1.24B AUM 21.71% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Curated Wealth Partners's AVIR Position: Q2 2026 in Review

Curated Wealth Partners opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 695,000 shares worth $671K. The stake represents 0.09% of the portfolio and ranks #208 among its holdings.

8 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Curated Wealth Partners held 695,000 shares of Atea Pharmaceuticals worth $671K as of Q2 2026.
  • Atea Pharmaceuticals was a new Curated Wealth Partners position in Q2 2026.
  • Atea Pharmaceuticals made up 0.09% of Curated Wealth Partners's portfolio in Q2 2026, its #208 holding.
  • 8 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Curated Wealth Partners's 13F filing for Q2 2026, filed 13 Jul 2026.